key takeaway 4: second-line regorafenib after tki in hcc
Published 5 years ago • 43 plays • Length 8:25Download video MP4
Download video MP3
Similar videos
-
2:04
dr. bruix on regorafenib in second-line hcc
-
1:09
survival benefit confirmed in real-life analysis of second-line regorafenib in hcc
-
2:05
dr. ghassan abou-alfa on second-line regorafenib in hcc
-
16:35
dr. finn on regorafenib for the treatment for patients with hcc
-
7:01
global use of regorafenib in hcc
-
4:30
regorafenib following first-line systemic therapy in hcc
-
7:09
global use of regorafenib in hcc
-
11:18
debate: is there a standard second line therapy for hcc? - regorafenib is a winner
-
1:28
dr. jordi bruix on efficacy and safety of regorafenib in hcc after sorafenib
-
4:11
second-line treatment for hepatocellular carcinoma
-
3:48
clinical experience with regorafenib in hcc
-
2:52
refine: a real-world analysis of regorafenib in patients with unresectable hcc
-
1:27
dr. sherman on the role of regorafenib in liver cancer
-
5:27
second-line systemic therapy in hcc
-
1:08
dr. bendell on fda approval of regorafenib in liver cancer
-
4:24
optimal use of second-line tkis in hepatocellular carcinoma
-
3:11
regorafenib in advanced hcc
-
1:34
dr. finn on the promise of regorafenib for the treatment of hcc
-
3:17
second-line systemic therapy in hcc